Cannabis Vaping Technology
for the 21st Century

Roxx has developed the first aqueous-based cannabis vaporizer.

Cannabis concentrates are highly viscous and are typically diluted with oils, PG/VG (propylene glycol and vegetable glycerin) and other potentially toxic additives to allow for the concentrates to be vaped.
Roxx’s proprietary technology enables vaping of cannabis concentrates free of oils, PG/VG and other toxic additives.

Equally important, Roxx’s proprietary technology enables several groundbreaking innovations, including:
• Medical grade metered dosing that ensures a specific dose per puff,
and puff-to-puff consistency.
• Production of a submicron aerosol that optimizes delivery of cannabis to
the deep lungs and bloodstream, thereby enhancing dose-response.
• Unrivalled sensory experience: Roxx’s soft, submicron aerosol also eliminates
the throat-burning sensation often experienced when vaping cannabis with
other devices.
• Discrete vaping, free of odors and smoke: Roxx vaporizers produce no odors
or exhalable smoke, empowering users to vape wherever and whenever without incumbering their surroundings.

Roxx has completed testing of its technology and is currently completing product design for manufacturing. Roxx plans to launch commercial sales by the end of Q2 2020.

Revolutionizing the Cannabis
Vaping Industry

Roxx aqueous-based vaporizers eliminate the risks associated with vaping concentrates mixed with oils, PG/VG and other potentially toxic additives.

For example, the American Lung Association recently cautioned that PG/VG exposes users to high levels of toxins that may cause lung disease.

Roxx’s proprietary technology enables vaping of cannabis concentrates free of oils, PG/VG and other toxic additives. 
Roxx is the first vaporizer to enable a safe and discrete experience, free of odors and exhalable smoke, and with no risk of secondhand smoke.

Unrivalled Performance

Roxx’s vaporizers produce a soft, submicron aerosol that optimizes delivery of cannabis to the deepest region of the lungs (alveoli).
This enables the rapid absorption of cannabis into the bloodstream, and significantly enhances absorbtion and the dose-effect experienced by the user.

Roxx vaporizers also enable an unrivalled sensory experience.

The aerosol produced by other vaping devices typically contain large particles and coarse droplets that cause the throat-burning sensation often experienced by users.

The submicron aerosol produced by Roxx vaporizers eliminates any throat-burning sensation and enables a smooth, relaxed sensory experience.

Equally important, Roxx vaporizers enable a discrete vaping experience. Roxx vaporizers do not produce any odors or smoke, allowing users to vape wherever and whenever without incumbering their surroundings.

Metered dosing

Roxx’s vaporizers enable medical grade metered dosing, empowering users to effectively manage their cannabis consumption.

Roxx’s vaporizers deliver a specific dose of cannabis with every puff, and ensure puff to puff consistency.

Roxx is currently completing product design for manufacturing, and will launch commercial sales by the end of Q2 2020.

Roxx is a subsidiary of Omega Life Sciences and is capitalizing on more than 8 years of R&D effort to develop proprietary pulmonary drug delivery technologies.


Yair Weinberger

Chairman of the Board

The major shareholder of Omega Life Sciences. COB of Electrotherm Group, Israel, specializing in the design, manufacturing, and sales of proprietary thermal process equipment to the global Aerospace industry.

Asaf Weinberger


CEO of Omega Life Science since 2011, where he raised over $10 million in equity capital, assembled a first class global team, and achieved key milestones for the company. Previously, served as an engineering officer (rank of captain) in the Israeli Defense Forces (IDF), and later as sales development engineer at Israel Aircraft Industries in Southeast Asia. Has an MBA and B.Sc. degree In Mechanical Engineering, from the Technion, Israel.

Dr. Miron Hazani


Held senior R&D positions in leading companies in the fields of microelectronics and nanotechnology. He holds a Ph.D. in Biochemistry from Tel Aviv University, and conducted post doctoral research in Chemistry, Physics and Nanotechnology at the Weizmann Institute of Science, Israel.

Dr. Jean-Philippe Selles

Director of Pharmaceutical Operations (OLS)

Held senior positions in a number of leading pharmaceutical companies and has vast experience in development strategies, scientific and regulatory affairs, alliances and mergers, and fund raising. He holds a Ph.D. in Biopharmacy and Pharmaceutical Sciences, and a Pharm. D. from the University of Montpellier, France.

Bill Morachnick


Served as President of Santa Fe Reynolds Tobacco International, GmbH (SFRTI) from 2006 until its acquisition by Japan Tobacco Group for $5B in 2016. Continued to serve as CEO and Chairman of SFRTI (renamed True Spirit Tobacco Company) until 2018. Vast experience in consumer marketing and brand development. Holds a B.A. (U of Maryland College Park), and MBA (Thunderbird School of Global Management).

Dr. Manfred Keller

Director of New Products Strategy (OLS)

Served for 11 years as Chief Scientific Officer and Exec. VP with PARI Pharma, Germany, a global leader in inhalation products. Previously served as Head of Aerosols and Inhalation with SkyePharma /JAGO, Switzerland, and as Head of Product Development and Pharmaceuticals at Ratiopharm, Germany. Holds a Ph.D. in Pharmacology from Freiburg University, Germany.

Contact Us

HaTaasiya Street, Ramat Gabriel Industrial Park,
Migdal HaEmeq, 2307041, Israel Fax: +972-4-6440652